GlassScriptPhysician profile
Andreas A Savopoulos
NPI 1972660496
$4,757.37
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,253 · 2020: $483 · 2021: $1,227 · 2022: $1,005 · 2023: $673 · 2024: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $624.98 | 2019-2023 | Lynparza, Imfinzi |
| Novartis Pharmaceuticals Corporation | $567.06 | 2019-2024 | |
| Janssen Biotech, INC. | $420.30 | 2019-2024 | Tecvayli, Darzalex |
| Incyte Corporation | $420.20 | 2019-2023 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $380.01 | 2019-2022 | |
| Lilly USA, LLC | $274.37 | 2019-2023 | Jaypirca, Verzenio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.79 | 2019-2023 | Gilotrif |
| Genzyme Corporation | $194.48 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $174.38 | 2019-2023 | |
| Pfizer INC. | $139.44 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $137.02 | 2019-2023 | Keytruda |
| Gilead Sciences, INC. | $133.47 | 2019-2023 | Trodelvy |
| Amgen INC. | $124.92 | 2019-2023 | Lumakras, Vectibix, Xgeva |
| Takeda Pharmaceuticals U.S.A., INC. | $120.59 | 2019-2023 | Alunbrig |
| Eisai INC. | $118.41 | 2019-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $104.36 | 2019-2023 | Reblozyl |
| Daiichi Sankyo INC. | $88.80 | 2021-2024 | Enhertu |
| Rigel Pharmaceuticals, INC. | $65.77 | 2019-2022 | |
| Glaxosmithkline, LLC. | $54.21 | 2020-2022 | |
| Puma Biotechnology, INC. | $49.08 | 2019-2020 | |
| Morphosys, US INC. | $33.19 | 2022 | |
| Apellis Pharmaceuticals, INC. | $32.09 | 2023 | Empaveli |
| Mirati Therapeutics, INC. | $31.16 | 2023 | Krazati |
| Cti Biopharma Corp. | $29.94 | 2023 | Vonjo |
| Dova Pharmaceuticals | $29.32 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $28.24 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $26.63 | 2019 | |
| Emmaus Medical, INC. | $24.71 | 2022 | |
| Secura Bio, INC. | $20.87 | 2022 | |
| Taiho Oncology, INC. | $19.26 | 2024 | |
| Macrogenics, INC. | $17.68 | 2022 | |
| Octapharma USA, INC. | $15.45 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.06 | 2020 | |
| Astellas Pharma US INC | $12.22 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.22 | 2019 | |
| Tesaro, INC. | $11.50 | 2019 | |
| Emd Serono, INC. | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andreas Savopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.